Predictive Technology Group (OTCPINK:PRED) announces that Predictive Therapeutics, its wholly-owned subsidiary, completed a crucial milestone in the development and commercialization of ARTGuide™.

As quoted in the press release:

Predictive Therapeutics, LLC anticipates its launch of a novel test for women experiencing infertility, as a result of endometriosis and other health concerns, called ARTGuide™.  The test is expected to change the way Advanced Reproductive Technologies (ART), such as In Vitro Fertilization (IVF), are used to help couples struggling to have a baby.  After testing thousands of women as part of the development program, the Company now expects commercial launch of the ARTGuide™ infertility test in the United States during Q3 2018.

Click here to read the full press release.